NewGenIvf Group (NASDAQ:NIVF) Director Kong Yiu Cheung Buys 2,500,000 Shares of Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung bought 2,500,000 shares of NewGenIvf Group stock in a transaction that occurred on Monday, July 27th. The shares were acquired at an average price of $1.00 per share, with a total value of $2,500,000.00. Following the acquisition, the director directly owned 3,722,223 shares of the company’s stock, valued at $3,722,223. The trade was a 204.55% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Thursday, June 18th, Kong Yiu Cheung purchased 500,000 shares of NewGenIvf Group stock. The stock was acquired at an average price of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF opened at $1.21 on Thursday. The company’s 50-day moving average price is $2.87 and its two-hundred day moving average price is $11.16. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98. NewGenIvf Group Limited has a one year low of $1.15 and a one year high of $1,539.00.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NIVF shares. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.